Cubist Systematic Strategies LLC cut its stake in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 65.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 48,365 shares of the company's stock after selling 92,168 shares during the period. Cubist Systematic Strategies LLC owned approximately 0.08% of Rezolute worth $237,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. acquired a new stake in shares of Rezolute during the third quarter valued at about $42,000. Geode Capital Management LLC grew its holdings in shares of Rezolute by 5.2% in the fourth quarter. Geode Capital Management LLC now owns 517,014 shares of the company's stock valued at $2,535,000 after purchasing an additional 25,413 shares in the last quarter. Barclays PLC acquired a new position in shares of Rezolute in the fourth quarter valued at approximately $314,000. Nantahala Capital Management LLC grew its holdings in shares of Rezolute by 10.9% in the fourth quarter. Nantahala Capital Management LLC now owns 2,857,982 shares of the company's stock valued at $14,004,000 after purchasing an additional 280,861 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Rezolute by 222.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 185,768 shares of the company's stock valued at $910,000 after purchasing an additional 128,190 shares in the last quarter. 82.97% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Rezolute
In related news, CEO Nevan C. Elam acquired 12,302 shares of Rezolute stock in a transaction dated Thursday, March 27th. The stock was acquired at an average price of $2.85 per share, for a total transaction of $35,060.70. Following the transaction, the chief executive officer now owns 224,119 shares of the company's stock, valued at $638,739.15. This represents a 5.81% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Daron Evans acquired 10,000 shares of Rezolute stock in a transaction dated Wednesday, March 26th. The shares were bought at an average price of $2.89 per share, with a total value of $28,900.00. Following the transaction, the chief financial officer now directly owns 237,900 shares in the company, valued at approximately $687,531. The trade was a 4.39% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 29,060 shares of company stock worth $83,694. 18.39% of the stock is currently owned by insiders.
Analyst Ratings Changes
A number of research analysts recently weighed in on RZLT shares. HC Wainwright restated a "buy" rating and issued a $14.00 price objective on shares of Rezolute in a report on Monday, April 28th. Craig Hallum upgraded shares of Rezolute to a "strong-buy" rating in a report on Tuesday, February 4th. Wedbush reiterated an "outperform" rating and set a $12.00 price target on shares of Rezolute in a report on Wednesday, May 14th. Guggenheim reiterated a "buy" rating on shares of Rezolute in a report on Monday, February 10th. Finally, JMP Securities boosted their price target on shares of Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $12.14.
Read Our Latest Stock Report on RZLT
Rezolute Price Performance
Shares of NASDAQ:RZLT traded down $0.01 during trading on Friday, hitting $3.89. 431,957 shares of the company were exchanged, compared to its average volume of 589,097. The stock has a market capitalization of $235.48 million, a P/E ratio of -3.19 and a beta of 1.01. Rezolute, Inc. has a 12-month low of $2.22 and a 12-month high of $6.19. The firm's 50 day moving average price is $3.27 and its 200-day moving average price is $4.25.
Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). As a group, equities research analysts anticipate that Rezolute, Inc. will post -0.93 EPS for the current year.
Rezolute Profile
(
Free Report)
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
Featured Stories
Before you consider Rezolute, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rezolute wasn't on the list.
While Rezolute currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
